Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Immunogenicity and Safety of Recombinant Vaccine Against Herpes Zoster (RZV or SHINGRIX®) in Patients With Autoimmune Rheumatic Diseases

NCT05879419 is registered in ClinicalTrials.gov with University of Sao Paulo General Hospital as lead sponsor.

NCT NCT05879419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05879419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Immunogenicity and Safety of Recombinant Vaccine Against Herpes Zoster (RZV or SHINGRIX®) in Patients With Autoimmune Rheumatic Diseases
Lead sponsor
University of Sao Paulo General Hospital
Phase
Phase 4
Overall status
Active, not recruiting
Start date
May 23, 2023
Completion date
June 30, 2032
Enrollment
2,005 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

behçet disease, dermatomyositis, juvenile, idiopathic inflammatory myopathies, juvenile idiopathic arthritis, rheumatoid arthritis, sjogren's syndrome, spondylitis, ankylosing, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, vasculitis, systemic